147 related articles for article (PubMed ID: 2076022)
1. Antitumor enzyme: polyethylene glycol-modified asparaginase.
Wada H; Imamura I; Sako M; Katagiri S; Tarui S; Nishimura H; Inada Y
Ann N Y Acad Sci; 1990; 613():95-108. PubMed ID: 2076022
[No Abstract] [Full Text] [Related]
2. Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
MacEwen EG; Rosenthal RC; Fox LE; Loar AS; Kurzman ID
J Vet Intern Med; 1992; 6(4):230-4. PubMed ID: 1522554
[TBL] [Abstract][Full Text] [Related]
3. Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma.
Teske E; Rutteman GR; van Heerde P; Misdorp W
Eur J Cancer; 1990; 26(8):891-5. PubMed ID: 2145933
[TBL] [Abstract][Full Text] [Related]
4. Asparaginase revisited.
Capizzi RL
Leuk Lymphoma; 1993; 10 Suppl():147-50. PubMed ID: 8481663
[No Abstract] [Full Text] [Related]
5. Prognostic factors for treatment of malignant lymphoma in dogs.
Teske E; van Heerde P; Rutteman GR; Kurzman ID; Moore PF; MacEwen EG
J Am Vet Med Assoc; 1994 Dec; 205(12):1722-8. PubMed ID: 7744644
[TBL] [Abstract][Full Text] [Related]
6. A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.
Agrawal NR; Bukowski RM; Rybicki LA; Kurtzberg J; Cohen LJ; Hussein MA
Cancer; 2003 Jul; 98(1):94-9. PubMed ID: 12833461
[TBL] [Abstract][Full Text] [Related]
7. Chemical modification of L-asparaginase with comb-shaped copolymer of poly(ethylene glycol) derivative and maleic anhydride.
Saito T; Ueno T; Sekine T; Kodera Y; Hiroto M; Matsushima A; Nishimura H; Inada Y
Leukemia; 1997 Apr; 11 Suppl 3():408-9. PubMed ID: 9209407
[TBL] [Abstract][Full Text] [Related]
8. L-asparaginase and PEG asparaginase--past, present, and future.
Keating MJ; Holmes R; Lerner S; Ho DH
Leuk Lymphoma; 1993; 10 Suppl():153-7. PubMed ID: 8481665
[TBL] [Abstract][Full Text] [Related]
9. [Progress in researches on anti-tumor agent L-asparaginase for treatment of leukemia].
Zhou J; Jin H; Li Y; Jiang T
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2000 Sep; 17(3):343-5. PubMed ID: 11285852
[TBL] [Abstract][Full Text] [Related]
10. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.
Abuchowski A; Kazo GM; Verhoest CR; Van Es T; Kafkewitz D; Nucci ML; Viau AT; Davis FF
Cancer Biochem Biophys; 1984 Jun; 7(2):175-86. PubMed ID: 6467175
[TBL] [Abstract][Full Text] [Related]
11. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
12. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
Jeffreys AB; Knapp DW; Carlton WW; Thomas RM; Bonney PL; Degortari A; Lucroy MD
J Am Anim Hosp Assoc; 2005; 41(4):221-6. PubMed ID: 15995158
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic pseudocyst in an adult patient after treatment with pegylated asparaginase.
van Galen KP; Zweegman S; Ossenkoppele GJ
Br J Haematol; 2011 Mar; 152(6):676. PubMed ID: 21623759
[No Abstract] [Full Text] [Related]
14. A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma.
MacEwen EG; Rosenthal R; Matus R; Viau AT; Abuchowski A
Cancer; 1987 Jun; 59(12):2011-5. PubMed ID: 3567863
[TBL] [Abstract][Full Text] [Related]
15. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
[TBL] [Abstract][Full Text] [Related]
16. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Yoshimoto T; Nishimura H; Saito Y; Sakurai K; Kamisaki Y; Wada H; Sako M; Tsujino G; Inada Y
Jpn J Cancer Res; 1986 Dec; 77(12):1264-70. PubMed ID: 3102431
[TBL] [Abstract][Full Text] [Related]
17. Two cases of pegylated asparaginase-associated severe and persistent hyperbilirubinemia.
Kim S
Am J Hematol; 2009 Oct; 84(10):696. PubMed ID: 19731309
[No Abstract] [Full Text] [Related]
18. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
Rathi B; Azad RK; Vasudha N; Hissaria P; Sawlani V; Gupta RK
Pediatr Neurosurg; 2002 Oct; 37(4):203-5. PubMed ID: 12372914
[TBL] [Abstract][Full Text] [Related]
19. Increased antitumor activity of Escherichia coli. L-asparaginase by modification with monomethoxypolyethylene glycol.
Kamisaki Y; Wada H; Yagura T; Nishimura H; Matsushima A; Inada Y
Gan; 1982 Jun; 73(3):470-4. PubMed ID: 6751921
[TBL] [Abstract][Full Text] [Related]
20. Epidural hematoma in a patient on pegylated-L-asparginase therapy.
Qubty WF; Mrelashvili A; Patterson MC
J Child Neurol; 2015 Apr; 30(5):636. PubMed ID: 24396128
[No Abstract] [Full Text] [Related]
[Next] [New Search]
